View Item 

Show simple item record

Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations
dc.contributor.authorXu, Yangen_US
dc.contributor.authorSun, Yanjunen_US
dc.contributor.authorShen, Hongjieen_US
dc.contributor.authorDing, Linen_US
dc.contributor.authorYang, Zhenen_US
dc.contributor.authorQiu, Huiyingen_US
dc.contributor.authorSun, Ainingen_US
dc.contributor.authorChen, Suningen_US
dc.contributor.authorWu, Depeien_US
dc.date.accessioned2015-11-12T21:04:28Z
dc.date.available2017-01-03T16:21:17Zen
dc.date.issued2015-11en_US
dc.identifier.citationXu, Yang; Sun, Yanjun; Shen, Hongjie; Ding, Lin; Yang, Zhen; Qiu, Huiying; Sun, Aining; Chen, Suning; Wu, Depei (2015). "Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations." American Journal of Hematology 90(11): 992-997.en_US
dc.identifier.issn0361-8609en_US
dc.identifier.issn1096-8652en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/115978
dc.publisherWiley Periodicals, Inc.en_US
dc.titleAllogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutationsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/115978/1/ajh24135.pdf
dc.identifier.doi10.1002/ajh.24135en_US
dc.identifier.sourceAmerican Journal of Hematologyen_US
dc.identifier.citedreferenceMarcucci G, Metzeler KH, Schwind S, et al. Age‐related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30: 742 – 750.en_US
dc.identifier.citedreferenceSchlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909 – 1918.en_US
dc.identifier.citedreferencePaschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636 – 3643.en_US
dc.identifier.citedreferenceNibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010; 116: 1132 – 1135.en_US
dc.identifier.citedreferenceShah MY, Licht JD. DNMT3A mutations in acute myeloid leukemia. Nat Genet 2011; 43: 289 – 290.en_US
dc.identifier.citedreferenceYan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309 – 315.en_US
dc.identifier.citedreferenceMizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172 – 1179.en_US
dc.identifier.citedreferenceLey TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424 – 2433.en_US
dc.identifier.citedreferenceIm AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia 2014; 28: 1774 – 1783.en_US
dc.identifier.citedreferenceThol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889 – 2896.en_US
dc.identifier.citedreferenceRenneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: A study by the Acute Leukemia French Association. Leukemia 2012; 26: 1247 – 1254.en_US
dc.identifier.citedreferenceRibeiro AF, Pratcorona M, Erpelinck‐Verschueren C, et al. Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia. Blood 2012; 119: 5824 – 5831.en_US
dc.identifier.citedreferenceOstronoff F, Othus M, Ho PA, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report. Leukemia 2013; 27: 238 – 241.en_US
dc.identifier.citedreferenceHou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications. Blood 2012; 119: 559 – 568.en_US
dc.identifier.citedreferenceShen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593 – 5603.en_US
dc.identifier.citedreferenceRoller A, Grossmann V, Bacher U, et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia 2013; 27: 1573 – 1578.en_US
dc.identifier.citedreferenceKoreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta‐analysis of prospective clinical trials. Jama 2009; 301: 2349 – 2361.en_US
dc.identifier.citedreferenceSchetelig J, Schaich M, Schäfer‐Eckart K, et al. Hematopoietic cell transplantation in patients with intermediate and high‐risk AML: Results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia 2015; 29: 1060 – 1068.en_US
dc.identifier.citedreferenceGaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: Results of the AML Study Group (AMLSG). Blood 2013; 121: 4769 – 4777.en_US
dc.identifier.citedreferencePatel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079 – 1089.en_US
dc.identifier.citedreferenceBejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem‐cell transplantation. J Clin Oncol 2014; 32: 2691 – 2698.en_US
dc.identifier.citedreferenceLoghavi S, Zuo Z, Ravandi F, et al. Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol 2014; 7: 74.en_US
dc.identifier.citedreferenceShlush LI, Zandi S, Mitchell A, et al. Identification of pre‐leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328 – 333.en_US
dc.identifier.citedreferencePløen GG, Nederby L, Guldberg P, et al. Persistence of DNMT3A mutations at long‐term remission in adult patients with AML. Br J Haematol 2014; 167: 478 – 486.en_US
dc.identifier.citedreferenceEstey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894 – 1907.en_US
dc.identifier.citedreferenceDombret H. Gene mutation and AML pathogenesis. Blood 2011; 118: 5366 – 5367.en_US
dc.identifier.citedreferenceThiede C, Steudel C, Mohr B, et al. Analysis of FLT3‐activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326 – 4335.en_US
dc.identifier.citedreferenceTaskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469 – 2475.en_US
dc.identifier.citedreferenceDöhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005; 106: 3740 – 3746.en_US
dc.identifier.citedreferenceDohner H, Estey EH, Amadori S, et al; European Leukemia Net. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453 – 474.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajh24135.pdf
Size:
583.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.